Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-07, Stock:NVS, The news for the past five days is as follows:
2019-02-28: NEWS1: Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates.NEWS2: Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates.NEWS3: Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates.NEWS4: Momenta Continues to Rebuild.NEWS5: Momenta Continues to Rebuild.NEWS6: Novartis faces shareholder criticism over drug prices at AGM.NEWS7: Novartis faces shareholder criticism over drug prices at AGM.NEWS8: Ionis Pharmaceuticals (IONS) Q4 2018 Earnings Conference Call Transcript.
2019-03-01: NEWS1: Novartis AG (NVS) Ex-Dividend Date Scheduled for March 04, 2019.NEWS2: Novartis AG (NVS) Ex-Dividend Date Scheduled for March 04, 2019.NEWS3: Novartis’ CEO is “un-bossing” his 125,000 employees.
2019-03-04: NEWS1: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates.
2019-03-05: NEWS1: FDA&apos;s Scott Gottlieb Resigns — What&apos;s Next For Biotech, Pharma?.NEWS2: Novartis has no plans to sell Sandoz - chairman.NEWS3: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings.
2019-03-06: NEWS1: The Roche Merger Will Do Wonders for Spark Stock.NEWS2: The Roche Merger Will Do Wonders for Spark Stock.NEWS3: Here's Why Ligand Pharmaceuticals Is Having a Bad Day.NEWS4: Here's Why Ligand Pharmaceuticals Is Having a Bad Day.NEWS5: Novartis or BMY: Who’s Expected to Report Faster EPS Growth?.NEWS6: NVS or BMY: Who’s Expected to Post Faster Revenue Growth in 2019?.NEWS7: Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT.NEWS8: Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT.NEWS9: What Analysts Are Recommending for Novartis and BMY.NEWS10: The Roche Merger Will Do Wonders for Spark Stock.NEWS11: Ligand Sells Promacta Rights for $827M, Updates '19 View.NEWS12: Ligand Sells Promacta Rights for $827M, Updates '19 View.NEWS13: Ligand Sells Promacta Rights for $827M, Updates '19 View.

Answer: Decrease